Please Scroll Down to See Forums Below Linares868
New member
I was going to do 10IU/day Monday through Friday nd take the weekends off. My goal is to gain as much size and strength as possible.
what would the best way be to take GH?
- Thread starter airtyme
- Start date
40butpumpin
New member
I have read that the amount to take per day depends on your body weight:
"0.1 IU per kg body weight daily is recommended"
Since I'm 245 lbs, that means a whopping:
0.1 IU / kg * 1 kg/ 2.2046 lb * 245 lb = 24.5/2.2046 = 11.11 IU's.
I was told to take it either right before bed or right after you wake up in the morning.
I'm very interested in what Anabolica said. 'eod is better than 5 on two off'. Can anyone corroborate that? I also heard not to take it every single day, but everyone seems to know that already.
"0.1 IU per kg body weight daily is recommended"
Since I'm 245 lbs, that means a whopping:
0.1 IU / kg * 1 kg/ 2.2046 lb * 245 lb = 24.5/2.2046 = 11.11 IU's.
I was told to take it either right before bed or right after you wake up in the morning.
I'm very interested in what Anabolica said. 'eod is better than 5 on two off'. Can anyone corroborate that? I also heard not to take it every single day, but everyone seems to know that already.
airtyme
New member
using the china blue tops, absolutely no complaints about the quality. I am getting sore wrist though. In a way that is good, since it is a side of GH in some individuals, it reinstates that fact that it is good shit. Not to mention, I did the "home pregnancy test" to make sure it wasn't HCG that I was getting. A buddy of mine was getting some type pf humatrope that looked a little fishy to me. He did the test as well and, to make a long story short-his shit was bunk!
40butpumpin
New member
Mr
Read the very last sentence of this...it's from:
http://www.smart-drugs.net/insert-hGH.htm
Human Growth Hormone (Lilly Humatrope®)
to order (prescription not required)
Ingredients- Each bottle contains 4 IU of biosynthetic human growth hormone (from recombinant DNA), excipients include Glycine, mannitol, bibasic sodium phosphate. Each bottle of dilutent contains m-cresol, glycerin, and water for injections.
Pharmaceutical Classification- Sterile freeze-dried powder of systemic hormone preparation.
Directions for use- Long-term treatment for stunted growth, due to the reduction or lack of somatotrophic endogenous hormone secretion in-patients who have not yet finished puberty. Treatment of short stature in girls suffering from Turner's syndrome confirmed by chromosomal analysis (the effect on final height has not yet been established).
Contraindications- Hypersensitivity in certain patients to the product or any of its ingredients. Patients with complete knitting of the epiphyses. Diabetes mellitus. Humatrope should not be used if there is any sign of active neoplasms. Endocrane lesions must be inactive and anti-tumoral treatment finished before beginning hormonal treatment. The use of Humatrope must be interrupted in the event of renewed tumoral growth. Humatrope must not be reconstituted with the accompanying dilutent if the patient is sensitive to m-cresol or glycerin.
Caution- Humatrope treatment should only be carried out under a doctor's authorization, by prescription, by university medical centers or hospitals specializing in the treatment of patients with growth hormone deficiency. Diagnoses must be confirmed before beginning Humatrope injections. This requires a clinical examination of the patient with detailed case histories, particularly with regard to auxilogical evaluations and the carrying out of laboratory tests, including stimulus test, to verify hypophysial hypothalamus functioning. Humatrope therapy should be carried out by a specialist in the diagnosis and treatment of patients related to stunted growth. Patients who, following diagnosis, undergo treatment with the somatotrophic hormone will have to be inscribed in a regional register and monitored by means of clinical auxilogical and laboratory evaluations every six months to check the functioning of the thyroid, glucide metabolism etc. The lack of available information may mean the exposure of the patient to a risk, which may exceed the therapeutic benefit obtained. Human hormone growth treatment should be complemented by an adequate supply of calories and amino acids. Once reconstituted with the accompanying dilutent, Humatrope can be taken in subcutaneous or intramuscular injections. Carcinogenesis, Mutagenesis and Fertility Alterations- Long term studies with Humatrope on animals have not been carried out, which would enable the evaluation of any carcinogenic or fertility altering effect which this pharmaceutical product may possibly have. No mutagenic effect due to Humatrope has been seen in tests up to the present.
Use during pregnancy and nursing- Studies on Humatrope and its effects on animal reproduction have not been carried out. It has not been seen that Humatrope can harm the fetus during pregnancy, nor that it can affect reproduction. Nevertheless, Humatrope should only be taken during pregnancy if absolutely necessary. Studies of the effects of Humatrope on nursing mothers have not been carried out and hence it is not known whether this product is excreted into mother's milk. However, since many pharmaceutical products are indeed passed into mother's milk, nursing mothers are advised to take Humatrope with extreme caution.
Interactions- Since taking Humatrope may cause resistance to insulin, patients should undergo periodic check ups in order to detect any intolerance to glucose. Children suffering from diabetes mellitus should be carefully supervised during Humatrope treatment, as it may be necessary to increase their insulin dosage. Excessive glucocortoid treatments may inhibit the effect of growth stimulation provided by the human somatotrophic hormone. In the case of patients who also suffer from ACTH (adrenocrticotrophic hormone) deficiency, the substitutive dosage of glucocorticoids must be accurately regulated in order to prevent any inhibitory effect on growth. Please Note- Attentive and constant supervision by the specialist is advised during growth hormone treatment of patients with neoplasms in remission. Those with a shortage of the growth hormone accompanying an endocrane lesion must be checked particularly frequently so as to prevent spreading or a relapse. Patients with growth hormone deficiency may frequently show alterations having to do with the epiphysis. For this reason, children who limp or show unsteadiness in their walking during growth hormone treatment should have thorough check ups. Hypothyroidism may arise during Humatrope treatment. Because untreated hypothyroidism can prevent an optimal response to Humatrope, patients should have periodic tests for thyroid functioning and undergo thyroid hormone treatment when necessary. Patients with psoriasis are also advised to have regular check ups so as to avoid a possible aggravation of the condition. In the event of sensitivity to the accompanying dilutent, the bottles may be reconstituted with sterile water for injections. If Humatrope is reconstituted this way, the solution must be administered within 24 hours and any left over solution thrown away. If, once reconstituted, the solution is not administered immediately, it may be kept up to 24 hours in the refrigerator at a temperature between +2 degrees Celsius and +8 degrees Celsius. Humatrope's effect on the patient's capacity to drive or operate machinery has not been determined.
Directions for use- Dosage and duration of treatment are to be decided by the specialist according to the needs of the patient. Patients with growth hormone deficiency- The recommended subcutaneous or intramuscular dosage is 0.18 mg/ kg of body weight (0.48 IU/ Kg) per week
0.48 IU / kg * 1 kg/ 2.2046 lb * 245 lb = 117.6/2.2046 = 53.34 IU's per week. Which works out to about 10.66 IU's per day if you're 5 on and 2 off.
That's Eli-Lilly's recommended dosage. The other I got from a different web site. (Chinese web site)
I really don't know if that's for heavy muscle growth or not, just says for Adult Onset Deficiency.
Hope that helps, bro.
Read the very last sentence of this...it's from:
http://www.smart-drugs.net/insert-hGH.htm
Human Growth Hormone (Lilly Humatrope®)
to order (prescription not required)
Ingredients- Each bottle contains 4 IU of biosynthetic human growth hormone (from recombinant DNA), excipients include Glycine, mannitol, bibasic sodium phosphate. Each bottle of dilutent contains m-cresol, glycerin, and water for injections.
Pharmaceutical Classification- Sterile freeze-dried powder of systemic hormone preparation.
Directions for use- Long-term treatment for stunted growth, due to the reduction or lack of somatotrophic endogenous hormone secretion in-patients who have not yet finished puberty. Treatment of short stature in girls suffering from Turner's syndrome confirmed by chromosomal analysis (the effect on final height has not yet been established).
Contraindications- Hypersensitivity in certain patients to the product or any of its ingredients. Patients with complete knitting of the epiphyses. Diabetes mellitus. Humatrope should not be used if there is any sign of active neoplasms. Endocrane lesions must be inactive and anti-tumoral treatment finished before beginning hormonal treatment. The use of Humatrope must be interrupted in the event of renewed tumoral growth. Humatrope must not be reconstituted with the accompanying dilutent if the patient is sensitive to m-cresol or glycerin.
Caution- Humatrope treatment should only be carried out under a doctor's authorization, by prescription, by university medical centers or hospitals specializing in the treatment of patients with growth hormone deficiency. Diagnoses must be confirmed before beginning Humatrope injections. This requires a clinical examination of the patient with detailed case histories, particularly with regard to auxilogical evaluations and the carrying out of laboratory tests, including stimulus test, to verify hypophysial hypothalamus functioning. Humatrope therapy should be carried out by a specialist in the diagnosis and treatment of patients related to stunted growth. Patients who, following diagnosis, undergo treatment with the somatotrophic hormone will have to be inscribed in a regional register and monitored by means of clinical auxilogical and laboratory evaluations every six months to check the functioning of the thyroid, glucide metabolism etc. The lack of available information may mean the exposure of the patient to a risk, which may exceed the therapeutic benefit obtained. Human hormone growth treatment should be complemented by an adequate supply of calories and amino acids. Once reconstituted with the accompanying dilutent, Humatrope can be taken in subcutaneous or intramuscular injections. Carcinogenesis, Mutagenesis and Fertility Alterations- Long term studies with Humatrope on animals have not been carried out, which would enable the evaluation of any carcinogenic or fertility altering effect which this pharmaceutical product may possibly have. No mutagenic effect due to Humatrope has been seen in tests up to the present.
Use during pregnancy and nursing- Studies on Humatrope and its effects on animal reproduction have not been carried out. It has not been seen that Humatrope can harm the fetus during pregnancy, nor that it can affect reproduction. Nevertheless, Humatrope should only be taken during pregnancy if absolutely necessary. Studies of the effects of Humatrope on nursing mothers have not been carried out and hence it is not known whether this product is excreted into mother's milk. However, since many pharmaceutical products are indeed passed into mother's milk, nursing mothers are advised to take Humatrope with extreme caution.
Interactions- Since taking Humatrope may cause resistance to insulin, patients should undergo periodic check ups in order to detect any intolerance to glucose. Children suffering from diabetes mellitus should be carefully supervised during Humatrope treatment, as it may be necessary to increase their insulin dosage. Excessive glucocortoid treatments may inhibit the effect of growth stimulation provided by the human somatotrophic hormone. In the case of patients who also suffer from ACTH (adrenocrticotrophic hormone) deficiency, the substitutive dosage of glucocorticoids must be accurately regulated in order to prevent any inhibitory effect on growth. Please Note- Attentive and constant supervision by the specialist is advised during growth hormone treatment of patients with neoplasms in remission. Those with a shortage of the growth hormone accompanying an endocrane lesion must be checked particularly frequently so as to prevent spreading or a relapse. Patients with growth hormone deficiency may frequently show alterations having to do with the epiphysis. For this reason, children who limp or show unsteadiness in their walking during growth hormone treatment should have thorough check ups. Hypothyroidism may arise during Humatrope treatment. Because untreated hypothyroidism can prevent an optimal response to Humatrope, patients should have periodic tests for thyroid functioning and undergo thyroid hormone treatment when necessary. Patients with psoriasis are also advised to have regular check ups so as to avoid a possible aggravation of the condition. In the event of sensitivity to the accompanying dilutent, the bottles may be reconstituted with sterile water for injections. If Humatrope is reconstituted this way, the solution must be administered within 24 hours and any left over solution thrown away. If, once reconstituted, the solution is not administered immediately, it may be kept up to 24 hours in the refrigerator at a temperature between +2 degrees Celsius and +8 degrees Celsius. Humatrope's effect on the patient's capacity to drive or operate machinery has not been determined.
Directions for use- Dosage and duration of treatment are to be decided by the specialist according to the needs of the patient. Patients with growth hormone deficiency- The recommended subcutaneous or intramuscular dosage is 0.18 mg/ kg of body weight (0.48 IU/ Kg) per week
0.48 IU / kg * 1 kg/ 2.2046 lb * 245 lb = 117.6/2.2046 = 53.34 IU's per week. Which works out to about 10.66 IU's per day if you're 5 on and 2 off.
That's Eli-Lilly's recommended dosage. The other I got from a different web site. (Chinese web site)
I really don't know if that's for heavy muscle growth or not, just says for Adult Onset Deficiency.
Hope that helps, bro.
40butpumpin
New member
Mr
Oh, I see. Sorry for the misunderstanding.
Oh, I see. Sorry for the misunderstanding.
BluePaddle
New member
Hi y'all, newbie/oldie here. 50-year-old woman, former competitive PL, WL & BB'er, currently kayaking (and of course, lifting) and looking to compete HARD in kayaking, slow down aging process + regain energy, strength, and size. Used to run a personal fitness training biz (didn't we ALL) and have degrees in Kinesiology (point being, I know my stuff.)
I weigh 177 lbs (80.3 kg) and have been taking 4 IU Humatrope intramuscularly 3 times a week, at night, for the last 23 days (yes, since Christmas!) and am really feeling FANTASTIC! Paddling intervals and wt training all improving greatly.
Question: am I really taking enough? I'm at 0.15 IU/kg/wk (0.0678 IU/lb/wk), and bear in mind I'm female and 50...but with huge competitive goals!
Thanks in advance from a golden oldie...
I weigh 177 lbs (80.3 kg) and have been taking 4 IU Humatrope intramuscularly 3 times a week, at night, for the last 23 days (yes, since Christmas!) and am really feeling FANTASTIC! Paddling intervals and wt training all improving greatly.
Question: am I really taking enough? I'm at 0.15 IU/kg/wk (0.0678 IU/lb/wk), and bear in mind I'm female and 50...but with huge competitive goals!
Thanks in advance from a golden oldie...
Similar threads
